Kailera Therapeutics Inc. Common Stock (KLRA)

FairStock Score: 19/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor in the Buffett-Graham tradition, I begin with what is knowable. Kailera is a clinical-stage biopharmaceutical company with 145 employees and a pipeline of injectable peptides, oral peptides, and oral small molecules for obesity and related conditions. That is a promising arena, but promising science is not a moat until it produces approved products and cash flows. The filed figures show no revenue. In fiscal Q2 2026, the quarter ended 2026-06-30, net income was -$111.3M and diluted EPS was -$1.09. A year earlier, in fiscal Q2 2025, the quarter ended 2025-06-30, net income was -$28.9M and diluted EPS was -$28,947.00. In fiscal Q1 2026, the quarter ended 2026-03-31, net income was -$78.9M versus -$18.0M in fiscal Q1 2025, the quarter ended 2025-03-31. Losses are widening materially. FairStock calculations show trailing free cash flow of -$190.3M and an FCF yield of -13.6%, a P/E of -4.79, P/B of 1.25, ROE of -36.90%, and ROCE of -22.73%. Debt is low at D/E 0.01, and the Altman Z-Score is 9.20, but the Piotroski F-Score is only 2/9 and the FairStock Score is 19/100. At the 2026-10-13 close of $10.77, the market cap is $1.4B. With no earnings, valuation rests on pipeline hopes, not on demonstrated earning power. The Lynch category is none because there are zero years of filed results and three are needed. I would need evidence of durable trial success and a path to funding without severe dilution before calling this a sound value proposition.

In plain English: Kailera Therapeutics is a drug research company in the early testing stage, trying to develop treatments for obesity and related conditions. The business looks weak right now: it has no reported revenue in the filed figures, is losing money, and is using cash. At $10.77 on 2026-10-13, the price looks expensive compared with its current numbers because there are no profits to support it; its value depends mostly on whether its drug tests succeed.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer